HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model.

UNLABELLED Many Human immunodeficiency virus (HIV) candidate vaccines have been tested in clinical trials, but none was sufficiently effective in the prevention of HIV infection. A HIV vaccine should induce humoral as well as cell-mediated response, the latter including the cytotoxic CD8+ T lymphocyte (CTL) response. In this study, we immunized BALB/c mice with a purified fusion peptide Gag p24-Nef and evaluated immune responses. As for the cellular responses, the adjuvanted fusion peptide induced lymphocyte proliferation, CTL response, and cytokines IFN-gamma and IL-4 in the Th1 pattern. Humoral immune response to the adjuvanted fusion peptide included an increase in IgG antibodies of more IgG2a than IgG1 subtype. These results indicate that the employed HIV-1 peptide construct can elicit both cellular and humoral immune responses in mice. Further studies aimed at memory T cells and other aspects of immune responses are needed before a comprehensive assessment of this candidate vaccine could be provided. KEYWORDS epitopes; fusion peptide; HIV-1 p24-Nef; immune response.

[1]  Abbas Jamali,et al.  A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. , 2009, International immunology.

[2]  B. Haynes,et al.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. , 2009, Vaccine.

[3]  B. Ensoli,et al.  Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. , 2008, Vaccine.

[4]  L. Thomsen,et al.  Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. , 2008, The Journal of general virology.

[5]  B. Autran,et al.  The Th1 immune response against HIV‐1 Gag p24‐derived peptides in mice expressing HLA‐A02.01 and HLA‐DR1 , 2007, European journal of immunology.

[6]  G. Pantaleo,et al.  Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. , 2007, Vaccine.

[7]  D. Birx,et al.  CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: Use of multiple peptide sets increases the detectable breadth of the CTL response , 2006, BMC Immunology.

[8]  Bette T. Korber,et al.  Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control , 2006, Journal of Virology.

[9]  Shixia Wang,et al.  Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. , 2006, Virology.

[10]  J. Mascola,et al.  Polyvalent DNA prime and envelope protein boost HIV‐1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate , 2005, Journal of medical primatology.

[11]  E. Sato,et al.  HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection , 2005, AIDS.

[12]  R. Paranjape,et al.  Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef. , 2005, The Journal of infectious diseases.

[13]  Scott A. Brown,et al.  Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. , 2005, Vaccine.

[14]  A. Srinivasan,et al.  Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens. , 2005, Virology.

[15]  M. Betts,et al.  Prime-Boost Vaccination with HIV-1 Gag Protein and Cytosine Phosphate Guanosine Oligodeoxynucleotide, Followed by Adenovirus, Induces Sustained and Robust Humoral and Cellular Immune Responses 1 , 2003, Journal of Immunology.

[16]  D. Strick,et al.  Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load , 2003, Journal of Virology.

[17]  J. Shiver,et al.  Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice. , 2002, Vaccine.

[18]  M. Kuroda,et al.  Potent CD4+ T Cell Responses Elicited by a Bicistronic HIV-1 DNA Vaccine Expressing gp120 and GM-CSF1 , 2002, The Journal of Immunology.

[19]  S. Calarota,et al.  Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. , 2001, Human gene therapy.

[20]  J. Guillet,et al.  DNA vaccination of macaques with several different Nef sequences induces multispecific T cell responses. , 2001, Virology.

[21]  Todd M. Allen,et al.  Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen1 , 2000, The Journal of Immunology.

[22]  T. Kepler,et al.  Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. , 1999, AIDS research and human retroviruses.

[23]  H. Bukawa,et al.  Strong augment effect of IL-12 expression plasmid on the induction of HIV-specific cytotoxic T lymphocyte activity by a peptide vaccine candidate. , 1997, Clinical immunology and immunopathology.

[24]  C. Rinaldo,et al.  High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors , 1995, Journal of virology.